AAAAAA

   
Results: 1-8 |
Results: 8
Correlation between tamoxifen elimination and biomarker recovery in a primary prevention trial
Authors: Guerrieri-Gonzaga, A Baglietto, L Johansson, H Bonanni, B Robertson, C Sandri, MT Canigiula, L Lampreda, C Diani, S Lien, EA Decensi, A
Citation: A. Guerrieri-gonzaga et al., Correlation between tamoxifen elimination and biomarker recovery in a primary prevention trial, CANC EPID B, 10(9), 2001, pp. 967-970
Epidemiology of prostate cancer
Authors: Boyle, P Gandini, S Baglietto, L Severi, G Robertson, C
Citation: P. Boyle et al., Epidemiology of prostate cancer, EUR UROL, 39, 2001, pp. 2-3
Autosomal dominant inheritance of prostate cancer: A confirmatory study
Authors: Verhage, BAJ Baffoe-Bonnie, AB Baglietto, L Smith, DS Bailey-Wilson, JE Beaty, TH Catalona, WJ Kiemeney, LA
Citation: Baj. Verhage et al., Autosomal dominant inheritance of prostate cancer: A confirmatory study, UROLOGY, 57(1), 2001, pp. 97-101
Analytical and graphical methods to model the association between family history and disease from a case-control study
Authors: Baglietto, L Severi, G Robertson, C Hopper, JL
Citation: L. Baglietto et al., Analytical and graphical methods to model the association between family history and disease from a case-control study, METH INF M, 40(2), 2001, pp. 112-116
Randomized trial of fenretinide in superficial bladder cancer using DNA flow cytometry as an intermediate end point
Authors: Decensi, A Torrisi, R Bruno, S Costantini, M Curotto, A Nicolo, G Malcangi, B Baglietto, L Bruttini, GP Gatteschi, B Rondanina, G Varaldo, M Perloff, M Malone, WF Bruzzi, P
Citation: A. Decensi et al., Randomized trial of fenretinide in superficial bladder cancer using DNA flow cytometry as an intermediate end point, CANC EPID B, 9(10), 2000, pp. 1071-1078
Assessment of DNA flow cytometry as a surrogate end point biomarker in a bladder cancer chemoprevention trial
Authors: Bruno, S Torrisi, R Costantini, M Baglietto, L Fontana, V Gatteschi, B Melioli, G Nicolo, G Curotto, A Malcangi, B Bruttini, GP Varaldo, M Bruzzi, P Decensi, A
Citation: S. Bruno et al., Assessment of DNA flow cytometry as a surrogate end point biomarker in a bladder cancer chemoprevention trial, J CELL BIOC, 76(2), 2000, pp. 311-321
Ocular effects of fenretinide, a vitamin A analog, in a chemoprevention trial of bladder cancer
Authors: Baglietto, L Torrisi, R Arena, G Tosetti, F Gonzaga, AG Pasquetti, W Robertson, C Decensi, A
Citation: L. Baglietto et al., Ocular effects of fenretinide, a vitamin A analog, in a chemoprevention trial of bladder cancer, CANCER DET, 24(4), 2000, pp. 369-375
Genotype/phenotype and penetrance studies in melanoma families with germline CDKN2A mutations
Authors: Bishop, JAN Wachsmuth, RC Harland, M Bataille, V Pinney, E Mack, P Baglietto, L Cuzick, J Bishop, DT
Citation: Jan. Bishop et al., Genotype/phenotype and penetrance studies in melanoma families with germline CDKN2A mutations, J INVES DER, 114(1), 2000, pp. 28-33
Risultati: 1-8 |